Baxter Jumps After Q2 Beat, Boosted 2026 Guidance Reflects Turnaround Progress
Baxter International Inc. (NYSE: BAX ) stock is trading higher on Thursday after the company reported better-than-expected second-quarter financial results and raised its fiscal 2026 guidance. • Baxter International shares are climbing with conviction. Why is BAX stock up today? Baxter Stock Gains After Q2 Earnings Beat, Raised 2026 Guidance The hospital product maker reported adjusted earnings of 54 cents, beating the consensus of 37 cents. The results reflect the roll-through of higher-cost inventory produced at the end of 2025, as well as an unfavorable comparison to the prior year related to the reclassification of certain functional costs from SG&A to cost of sales. These impacts were partially offset by a 11 cents per diluted share benefit related to an IEEPA tariff refund. Sales increased 5% to $2.96 billion, beating the consensus of $2.795 billion, led by advanced surgery and...
Baxter International Inc. (NYSE: BAX ) stock is trading higher on Thursday after the company reported better-than-expected second-quarter financial results and raised its fiscal 2026 guidance. • Baxter International shares are climbing with conviction. Why is BAX stock up today?
Baxter Stock Gains After Q2 Earnings Beat, Raised 2026 Guidance The hospital product maker reported adjusted earnings of 54 cents, beating the consensus of 37 cents. The results reflect the roll-through of higher-cost inventory produced at the end of 2025, as well as an unfavorable comparison to the prior year related to the reclassification of certain functional costs from SG&A to cost of sales. These impacts were partially offset by a 11 cents per diluted share benefit related to an IEEPA tariff refund. 795 billion, led by advanced surgery and drug compounding.
” “We are still early in our turnaround and have more work ahead of us. 1 billion, increasing 7% on a reported basis and 5% on an organic basis. The growth reflects strength within the Infusion Therapies & Platforms division, driven primarily by Drug Compounding and IV Solutions, partially offset by reduced sales within Infusion Systems, due to the previously disclosed shipment and installation hold of the Novum IQ LVP and Injectables. Continued strong global demand for Advanced Surgery products also contributed to performance.
Healthcare Systems & Technologies revenues were approximately $801 million, increasing 4% on both a reported and organic basis, led by strong demand for Care & Connectivity Solutions products, driven by growth in Patient Support Systems. Results also reflected growth in Front Line Care. 91. 357 billion.
The company expects margins to expand in the second half of the year, driven by higher volumes consistent with typical seasonality, benefits from cost-structure actions, and the roll-through of higher-cost inventory shifting. 49 at the time of publication on Thursday, according to Pro data. Photo via Shutterstock Read Also: Rising Memory Costs Are Hurting Smartphones, Qualcomm Warns